In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

In many parts of the country, COVID cases are rising — but the tracking data isn't as reliable as it once was. ljubaphoto via ...

Coronavirus cases may surge in the coming weeks, as they have every summer since the pandemic began five years ago, experts ...

COVID antiviral Paxlovid to see price increase following 400% vaccine hike The new price is not set, but one analyst suggested it could be up to 5x higher.

The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to new research by UCLA doctors. The findings, published Thursday in a ...

Pfizer reported $12.5 billion in Paxlovid and COVID vaccine sales in 2023, after a $57 billion peak in 2022. The company's 2024 Super Bowl ad, which cost an estimated $14 million to place, ...

Scientists are currently studying how well people are protected against severe disease from XFG. Researchers conducted lab ...

An extremely painful sore throat, often now referred to as “razor blade throat”, is just one of the several symptoms of a new ...

Vaccines and treatments together offer optimal protection against covid’s severe outcomes. Each reduces the risk of hospitalization and death, though Paxlovid probably has the greater effect.

Paxlovid was linked with a 26% lower risk of long Covid, a 47% lower risk of death and a 24% lower risk of hospitalization 30 days after an initial infection.

$1,650 COVID-19 treatment called into question after major study In a nutshell A major study of 1.6 million seniors found that Paxlovid, while widely prescribed, did not significantly reduce COVID ...

Most patients in the analysis (87.5%) had received at least two COVID-19 vaccines, potentially explaining the different outcomes compared to earlier studies in unvaccinated populations.